Acute pancreatitis secondary to topical and oral treatment with mesalamine in a patient with ulcerative colitis

Abstract

AbstrAct Introduction: Derivatives of 5-aminosalicylic acid (5-AsA) as claversal® used for the treatment of inflammatory bowel disease may induce acute pancreatitis both orally as topically. Mesalazine is the only treatment used in our environment within the compounds of 5-AsA, due to other molecules not being available. It is available for both oral and topical, being topical form highly relevant considering that its compounds are rapidly absorbed once acetylated, resulting in inactive metabolites. Nowadays the mechanism or pathway by which it is produced is not really clear, neither the relationship with the intervals between exposure of treatment nor the onset of clinical symptoms, due to some cases in which there was no relationship with the duration, which was our case. case report: We report one case of 5-AsA induced pancreatitis. A 35-year-old male whose first episode was secondary to oral form with subsequent recurrence after beginning with topical form. conclusion: We would like to point out that after an episode of pancreatitis due to oral mesalamine, topical mesalamine should not be prescribed